Ursodeoxycholic Acid (Ursodiol): Indications and Dosing
Primary Biliary Cholangitis (PBC)
Ursodeoxycholic acid at 13-15 mg/kg/day is the first-line treatment for all patients with PBC and should be initiated immediately upon diagnosis. 1, 2
Dosing for PBC
- Standard dose: 13-15 mg/kg/day divided into 2-3 doses 1
- This dosing improves liver biochemistry, delays histological progression, and reduces the likelihood of liver transplantation or death, particularly in patients with moderate to severe disease 1
- Do not exceed 15 mg/kg/day - higher doses provide no additional benefit and increasing beyond this threshold is not indicated even for persistent alkaline phosphatase elevation 2
- Continue UDCA even if alkaline phosphatase remains elevated, as it still provides sustained survival benefits 2
Key Clinical Points for PBC
- UDCA works through multiple mechanisms: protecting cholangiocytes from toxic bile acids, stimulating hepatobiliary secretion, and inhibiting apoptosis 1
- Biochemical response should be assessed at 1 year, with near-normalization of alkaline phosphatase as the target 3
- Approximately two-thirds of patients respond adequately to UDCA 3
- Critical pitfall: Many patients in the UK are underdosed; over one-third of partial responders become full responders when UDCA is increased to the recommended 13-15 mg/kg/day 3
- UDCA is safe during pregnancy and breastfeeding and should be continued 4
Primary Sclerosing Cholangitis (PSC)
UDCA is NOT recommended for routine treatment of newly diagnosed PSC. 5, 6
Evidence Against Use in PSC
- Multiple trials show UDCA improves liver biochemistry but does not improve clinical outcomes (death, transplantation, or disease progression) 5, 6
- High-dose UDCA (28-30 mg/kg/day) is harmful - a multicenter trial was terminated early due to increased rates of death, liver transplantation, and variceal development in the UDCA group 6, 1, 6
- Low to moderate doses (10-23 mg/kg/day) show no survival benefit 5, 1, 6
Exception
- In PSC with autoimmune hepatitis overlap syndrome, corticosteroids and immunosuppressants are recommended, not UDCA 5
Cholesterol Gallstone Dissolution
For radiolucent cholesterol gallstones: 8-10 mg/kg/day divided into 2-3 doses. 7
Dosing and Monitoring for Gallstones
- FDA-approved dose: 8-10 mg/kg/day 7
- Ultrasound monitoring at 6-month intervals during the first year 7
- Complete dissolution expected in approximately 30% of unselected patients with uncalcified stones <20 mm treated for up to 2 years 7
- Best candidates: Floating stones (high cholesterol content), stones ≤5 mm diameter (81% dissolution rate), stones <20 mm 7
- Poor candidates: Calcified stones, stones >20 mm, non-visualizing gallbladder on treatment 7
Treatment Duration and Outcomes
- If partial dissolution is not seen by 12 months, likelihood of success is greatly reduced 7
- Continue therapy after apparent dissolution and confirm on repeat ultrasound within 1-3 months 7
- Stone recurrence occurs in 30-50% of patients within 2-5 years after complete dissolution 7
Alternative Dosing Strategy
- Bedtime administration at 8.4 mg/kg/day may be more effective than divided mealtime dosing, reducing the cholesterol saturation index more efficiently 8
Gallstone Prevention During Rapid Weight Loss
For obese patients undergoing rapid weight loss: 600 mg/day (300 mg twice daily). 7
This prophylactic dose is specifically for patients with BMI ≥38 undergoing very low-calorie diets 7.